ハーセプチンの世界市場レポート2025年

ハーセプチン市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.1％で95億9,000万米ドルに成長します。予測期間中の成長は、バイオシミラーの拡大、標的治療薬の採用拡大、新興国市場でのヘルスケアアクセスの改善、進行中のがん領域の研究開発、HER2陽性がんの有病率の上昇などに起因すると考えられます。予測期間における主な動向としては、抗体薬物複合体の開発、バイオシミラー製剤の進展、創薬におけるAIの統合、個別化医療アプローチ、ドラッグデリバリーシステムの改善などが挙げられます。

乳がんの罹患率の増加がハーセプチン市場の拡大を牽引すると予想されます。乳房の細胞で開発される乳がんは、一般的に乳管や小葉から始まり、浸潤性乳管がん（IDC）、浸潤性小葉がん（ILC）、HER2陽性乳がんなどのタイプがあります。乳がん患者の増加は、アルコール摂取量の増加、食生活の乱れ、運動不足などの生活習慣が一因であり、これらすべてがリスクの上昇に寄与しています。特にHER2陽性乳がんと診断され、治療を希望する人が増えるにつれて、ハーセプチンのような効果的な分子標的治療薬に対する需要は増加の一途をたどっています。例えば、2025年1月、米国がん学会は、米国における乳がんの新規患者数は約31万9,750人、死亡者数は4万2,680人と予測しています。したがって、乳がんの罹患率の増加がハーセプチン市場の成長に拍車をかけています。

ハーセプチン市場の主要企業は、患者アクセスを改善し、HER2陽性がんの治療成績を向上させるために、革新的なバイオシミラー製品を開発しています。バイオシミラーとは、承認された生物学的製剤の高度に類似したバージョンであり、同等の安全性、有効性、品質を確保するために高度なバイオテクノロジーを駆使して開発されます。例えば、米国を拠点とする製薬会社Accord BioPharma Inc.は2024年4月、HER2過剰発現乳がんおよび胃がんの治療薬として、ハーセプチンのバイオシミラーであるHERCESSI（trastuzumab-strf）の承認を米国食品医薬品局から取得しました。HERCESSIのようなバイオシミラーは、先発の生物学的製剤と同等の有効性と安全性を維持しながら、患者に費用対効果の高い治療選択肢を提供します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のハーセプチンPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のハーセプチン市場：成長率分析
• 世界のハーセプチン市場の実績：規模と成長、2019年～2024年
• 世界のハーセプチン市場の予測：規模と成長、2024年～2029年、2034年
• 世界のハーセプチン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のハーセプチン市場：製品別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 生物学的製剤
• バイオシミラー
• 世界のハーセプチン市場：用途別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 乳がん
• 胃がん
• 世界のハーセプチン市場：支払者別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 商業用および個人用
• 公共
• 世界のハーセプチン市場：流通チャネル別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院薬局
• 専門薬局
• 世界のハーセプチン市場、生物学的製剤の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• 静脈内（IV）生物学的製剤
• 皮下（SC）生物学的製剤
• 世界のハーセプチン市場、バイオシミラーの種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• 静脈内（IV）バイオシミラー
• 皮下（SC）バイオシミラー

第7章 地域別・国別分析

• 世界のハーセプチン市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 世界のハーセプチン市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ハーセプチン市場：競合情勢
• ハーセプチン市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Viatris Inc.
• Teva Pharmaceutical Industries Ltd
• Boehringer Ingelheim GmbH
• Genentech Inc.
• Dr. Reddy's Laboratories
• Celltrion Healthcare
• Mundipharma
• Biocon Limited
• Bio-Techne Corporation
• Samsung Bioepis Co Ltd
• AryoGen Pharmed
• InvivoGen
• Abnova Corporation
• Shanghai Henlius Biotech Inc
• Prestige Biopharma Pte Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ハーセプチン市場2029年：新たな機会を提供する国
• ハーセプチン市場2029年：新たな機会を提供するセグメント
• ハーセプチン市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Herceptin, also known as trastuzumab, is a monoclonal antibody used to treat HER2-positive breast and gastric cancers. It specifically targets the HER2/neu receptor, which promotes the growth of cancer cells. By binding to this receptor, Herceptin inhibits tumor cell proliferation and marks them for destruction by the immune system.

The main products of Herceptin include biologics and biosimilars. Biologics are complex, large-molecule drugs derived from living organisms, used to treat various diseases, including cancer. The key payers include commercial, private, and public sectors, with applications in the treatment of breast and gastric cancers. Treatment is distributed through various channels, such as hospital pharmacies and specialty pharmacies.

The herceptin market research report is one of a series of new reports from The Business Research Company that provides herceptin market statistics, including herceptin industry global market size, regional shares, competitors with a herceptin market share, detailed herceptin market segments, market trends and opportunities, and any further data you may need to thrive in the herceptin industry. The herceptin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The herceptin market size has grown strongly in recent years. It will grow from$7.10 billion in 2024 to $7.55 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth during the historic period can be attributed to regulatory approvals, the rising incidence of breast cancer, advancements in monoclonal antibody technology, positive clinical trial outcomes, and increasing healthcare expenditure.

The herceptin market size is expected to see strong growth in the next few years. It will grow to$9.59 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth during the forecast period can be attributed to the expansion of biosimilars, increasing adoption of targeted therapies, improved healthcare access in emerging markets, ongoing research and development in oncology, and the rising prevalence of HER2-positive cancers. Key trends in the forecast period include the development of antibody-drug conjugates, advancements in biosimilar formulations, the integration of AI in drug discovery, personalized medicine approaches, and improvements in drug delivery systems.

The growing incidence of breast cancer is expected to drive the expansion of the Herceptin market. Breast cancer, which develops in the cells of the breast, typically starts in the milk ducts or lobules, and includes types such as invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), and HER2-positive breast cancer. The rise in breast cancer cases is partly attributed to lifestyle factors such as higher alcohol consumption, poor diet, and a lack of physical activity, all of which contribute to a higher risk. As more individuals, particularly those diagnosed with HER2-positive breast cancer, are seeking treatment, the demand for effective targeted therapies such as Herceptin continues to grow. For instance, in January 2025, the American Cancer Society projected approximately 319,750 new cases of breast cancer in the U.S. with 42,680 expected deaths. Therefore, the increasing incidence of breast cancer is fueling the growth of the Herceptin market.

Leading companies in the Herceptin market are developing innovative biosimilar products to improve patient access and enhance therapeutic outcomes for HER2-positive cancers. Biosimilars are highly similar versions of approved biologic drugs, developed using advanced biotechnology to ensure comparable safety, efficacy, and quality. For example, in April 2024, Accord BioPharma Inc., a U.S.-based pharmaceutical company, received approval from the U.S. Food and Drug Administration for HERCESSI (trastuzumab-strf), a biosimilar to Herceptin, for the treatment of HER2-overexpressing breast and gastric cancers. Biosimilars such as HERCESSI provide patients with a cost-effective treatment option while maintaining comparable efficacy and safety to the original biologic drug.

In December 2022, Celltrion Inc., a South Korea-based biopharmaceutical company, merged with Celltrion Healthcare Co. to enhance its cost competitiveness and diversify its product pipeline. This merger is designed to streamline operations, boost research investments, and simplify the company's structure. Celltrion Healthcare Co., known for developing the Herceptin biosimilar Herzuma (trastuzumab-pkrb), which was approved by the FDA, is now positioned to further strengthen its global biopharma presence following this strategic merger.

Major players in the herceptin market are Pfizer Inc., Roche Holding AG, Merck & Co Inc., GlaxoSmithKline plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim GmbH, Genentech Inc., Dr. Reddy's Laboratories, Celltrion Healthcare, Mundipharma, Biocon Limited, Bio-Techne Corporation, Samsung Bioepis Co Ltd, AryoGen Pharmed, InvivoGen, Abnova Corporation, Shanghai Henlius Biotech Inc., and Prestige Biopharma Pte Ltd.

North America was the largest region in the herceptin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in herceptin report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the herceptin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The herceptin market consists of sales of trastuzumab, trastuzumab deruxtecan, and ado-trastuzumab emtansine. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Herceptin Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on herceptin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for herceptin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The herceptin market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Biologic; Biosimilar
• 2) By Application: Breast Cancer; Gastric Cancer
• 3) By Payer: Commercial And Private; Public
• 4) By Distribution Channel: Hospital Pharmacy; Specialty Pharmacy
• Subsegments:
• 1) By Biologic: Intravenous (IV) Biologics; Subcutaneous (SC) Biologic
• 2) By Biosimilar: Intravenous (IV) Biosimilars; Subcutaneous (SC) Biosimilars
• Companies Mentioned: Pfizer Inc.; Roche Holding AG; Merck & Co Inc.; GlaxoSmithKline plc; Amgen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Herceptin Market Characteristics

3. Herceptin Market Trends And Strategies

4. Herceptin Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Herceptin Growth Analysis And Strategic Analysis Framework

• 5.1. Global Herceptin PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Herceptin Market Growth Rate Analysis
• 5.4. Global Herceptin Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Herceptin Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Herceptin Total Addressable Market (TAM)

6. Herceptin Market Segmentation

• 6.1. Global Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biologic
• Biosimilar
• 6.2. Global Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Breast Cancer
• Stomach Or Gastric Cancer
• 6.3. Global Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Commercial And Private
• Public
• 6.4. Global Herceptin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Specialty Pharmacy
• 6.5. Global Herceptin Market, Sub-Segmentation Of Biologic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous (IV) Biologics
• Subcutaneous (SC) Biologic
• 6.6. Global Herceptin Market, Sub-Segmentation Of Biosimilar, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous (IV) Biosimilars
• Subcutaneous (SC) Biosimilars

7. Herceptin Market Regional And Country Analysis

• 7.1. Global Herceptin Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Herceptin Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Herceptin Market

• 8.1. Asia-Pacific Herceptin Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Herceptin Market

• 9.1. China Herceptin Market Overview
• 9.2. China Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Herceptin Market

• 10.1. India Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Herceptin Market

• 11.1. Japan Herceptin Market Overview
• 11.2. Japan Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Herceptin Market

• 12.1. Australia Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Herceptin Market

• 13.1. Indonesia Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Herceptin Market

• 14.1. South Korea Herceptin Market Overview
• 14.2. South Korea Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Herceptin Market

• 15.1. Western Europe Herceptin Market Overview
• 15.2. Western Europe Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Herceptin Market

• 16.1. UK Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Herceptin Market

• 17.1. Germany Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Herceptin Market

• 18.1. France Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Herceptin Market

• 19.1. Italy Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Herceptin Market

• 20.1. Spain Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Herceptin Market

• 21.1. Eastern Europe Herceptin Market Overview
• 21.2. Eastern Europe Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Herceptin Market

• 22.1. Russia Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Herceptin Market

• 23.1. North America Herceptin Market Overview
• 23.2. North America Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Herceptin Market

• 24.1. USA Herceptin Market Overview
• 24.2. USA Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Herceptin Market

• 25.1. Canada Herceptin Market Overview
• 25.2. Canada Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Herceptin Market

• 26.1. South America Herceptin Market Overview
• 26.2. South America Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Herceptin Market

• 27.1. Brazil Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Herceptin Market

• 28.1. Middle East Herceptin Market Overview
• 28.2. Middle East Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Herceptin Market

• 29.1. Africa Herceptin Market Overview
• 29.2. Africa Herceptin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Herceptin Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Herceptin Market, Segmentation By Payer, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Herceptin Market Competitive Landscape And Company Profiles

• 30.1. Herceptin Market Competitive Landscape
• 30.2. Herceptin Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Herceptin Market Other Major And Innovative Companies

• 31.1. Viatris Inc.
• 31.2. Teva Pharmaceutical Industries Ltd
• 31.3. Boehringer Ingelheim GmbH
• 31.4. Genentech Inc.
• 31.5. Dr. Reddy's Laboratories
• 31.6. Celltrion Healthcare
• 31.7. Mundipharma
• 31.8. Biocon Limited
• 31.9. Bio-Techne Corporation
• 31.10. Samsung Bioepis Co Ltd
• 31.11. AryoGen Pharmed
• 31.12. InvivoGen
• 31.13. Abnova Corporation
• 31.14. Shanghai Henlius Biotech Inc
• 31.15. Prestige Biopharma Pte Ltd.

32. Global Herceptin Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Herceptin Market

34. Recent Developments In The Herceptin Market

35. Herceptin Market High Potential Countries, Segments and Strategies

• 35.1 Herceptin Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Herceptin Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Herceptin Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer